Johnson & Johnson to Begin Coronavirus Vaccine Clinical Trial in July
Johnson & Johnson (NYSE: JNJ) announced on Wednesday that it expects to begin a phase 1/2a clinical trial of its COVID-19 vaccine candidate Ad26.COV2-S, recombinant, in the second half of July. The company previously projected that the early-stage clinical study would begin in September.
In February, Johnson & Johnson established a partnership with BARDA (the Biomedical Advanced Research and Development Authority) to develop a COVID-19 vaccine candidate at an accelerated pace. Chief Scientific Officer Paul Stoffels noted that the strong preclinical data observed thus far and the company's discussions with regulatory authorities were key in allowing it to speed up the development program.
Image source: Getty Images.
Source Fool.com